电针对常年性变应性鼻炎患者血浆血管活性肠肽和P物质的影响

Effects of Electroacupuncture on Plasma Vasoactive Intestinal Peptide and Substance P in Perennial Allergic Rhinitis Patients

目的:探讨电针蝶腭神经节为主治疗常年性变应性鼻炎(PAR)的神经免疫学机制。方法:将100例PAR患者随机分为治疗组和对照组,其中治疗组选取蝶腭神经节、印堂、迎香、上迎香为主穴进行电针治疗,对照组于饭后口服西替利嗪片,10mg/次,每日3次,分别于治疗前及治疗3个疗程后观察其血浆血管活性肠肽(VIP)和P物质(SP)水平的变化。结果:治疗3个疗程后,治疗组的VIP和SP水平均明显降低,与治疗前比较具有显著性统计学差异(P<0.01,0.05);与对照组相比,治疗组对VIP水平的影响更为明显(P<0.05)。结论:电针蝶腭神经节为主的方法能显著降低PAR患者升高的鼻神经肽,推测电针蝶腭神经节为主治疗PAR可能是通过调节鼻神经肽类物质,控制鼻神经源炎而发挥其治疗作用的。

Objective： To explore the underlying neuroimmunological mechanism of electroacupuncture （EA） in the treatmerit of perennial allergic rhinitis （PAR）, Methods： One hundred PAR outpatients were evenly randomized into EA group and medication group. Patients in EA group were treated with EA （5- 10 mA, 80- 100 Hz, and 30 min of stimulation） of Sphenopalatine ganglion area, Yingxiang （LI 20）, Shangyingxiang （EX-HN 8）, Yintang （EX-HN 3）, supplemented with other acupoints according to syndrome-differentiation （once daily, 10 days being a therapeutic course）. Patients of medication group were treated by Oetirizine （ 10 mg/times, t. i. d, peros）. Before and after the treatment, blood samples of the ulnar vein were collected for detecting plasma vasoactive intestinal peptide （VIP） and substance P （SP） contents with radioimmunoassay. Results： After the treatment, of the two 50 cases in EA and medication groups, 20 （40%） and 16 （32%） had an obvious improvement, 28 （56%） and 24 （48 % ） had an improvement, 2 （4 % ） and 10 （20 % ） failed, with the total effective rates being 96 % and 80 % separately. The therapeutic effect of EA group was significantly superior to that of medication group （P〈0.05）, Self-comparison of each group showed that after the treatment, both plasma VIP and SP levels of two groups lowered apparently （P〈0.05, 0.01 ）. Comparison between two groups showed that after the treatment, the content of VIP in EA group was markedly lower than that of medication group, while no significant difference was found between two groups in plasma SP levels （P〉0.05）. Conclusion： EA can effectively relieve perennial allergic rhinitis patients＇ clinical symptoms, which is closely related to its functions in lowering plasma VIP and SP levels.